SCHEMBL185903

SCHEMBL185903

CC(=O)c1ccc(Nc2ccc(F)cc2C(F)(F)F)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.44
FLT3 P36888 1/20 0.44
DHODH Q02127 1/20 0.40
AR P10275 1/20 0.39
KDR P35968 1/20 0.39
AURKA O14965 2/20 0.39
CHEK2 O96017 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
FLT4 P35916 1/20 0.39
ABL2 P42684 1/20 0.39
BLK P51451 1/20 0.39
LIMK1 P53667 1/20 0.39
AURKB Q96GD4 1/20 0.39
MAPK10 P53779 1/20 0.39
HDAC3 O15379 4/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC2 Q92769 3/20 0.38
NCOR2 Q9Y618 3/20 0.38
PTK2 Q05397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184967 0.88 KIT (0.42) KITFLT3DHODHARKDR
SCHEMBL186306 0.88 RAB9A (0.46) KITFLT3DHODHKDRMAPK10
SCHEMBL185950 0.87 FLT3 (0.55) KITFLT3MAPK10HDAC3HDAC1
Hydrochloric Acid SCHEMBL2805862 0.86 FLT3 (0.54) KITFLT3MAPK10HDAC3HDAC1
SCHEMBL2808253 0.85 KIT (0.38) KITFLT3DHODHKDRAURKA
SCHEMBL2808251 0.85 KIT (0.38) KITFLT3DHODHKDRAURKA
SCHEMBL185082 0.85 KIT (0.38) KITFLT3DHODHKDRAURKA
SCHEMBL185694 0.84 AKR1C3 (0.47) KITFLT3DHODHAURKAAKR1C3
SCHEMBL27853654 0.79 DHODH (0.38) DHODHAURKACHEK2CSF1RRET
SCHEMBL27853712 0.76 ACP1 (0.35) KITFLT3DHODHAURKACHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
EP-2401256-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-01-04 EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 KIT 989/4885FLT3 632/4885DHODH 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.